Rochester, Minn.-based Mayo Clinic has developed an AI model to screen for cardiac amyloidosis, a rare, progressive type of heart failure.
The health system built the solution, the first and only of its kind, with AI echocardiography company Ultromics and validated it with researchers from University of Chicago Medicine. They found that the AI tool correctly identified patients with the disease 85% of the time and without 93% of the time.
“This AI model is a breakthrough tool that can help us identify patients earlier so they can receive the treatment they need,” said Patricia Pellikka, MD, a Mayo Clinic cardiologist and past director of the Mayo Clinic Echocardiography Lab, in a July 9 news release. “We found that AI performed better than traditional clinical and transthoracic echo-based screening methods, providing clinicians with stronger insights on which to base decisions for further confirmation tests.”
The tool has been cleared by the FDA and is in use in multiple centers across the U.S.
